` 603858 (Shandong Buchang Pharmaceuticals Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

603858
vs
S
Shanghai Composite

Over the past 12 months, Shandong Buchang Pharmaceuticals Co Ltd has underperformed Shanghai Composite, delivering a return of +14% compared to the Shanghai Composite's +25% growth.

Stocks Performance
603858 vs Shanghai Composite

Loading
603858
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
603858 vs Shanghai Composite

Loading
603858
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
603858 vs Shanghai Composite

Loading
603858
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Shandong Buchang Pharmaceuticals Co Ltd vs Peers

Shanghai Composite
603858
JEF
JNJ
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Shandong Buchang Pharmaceuticals Co Ltd
Glance View

Market Cap
17.9B CNY
Industry
Pharmaceuticals

Shandong Buchang Pharmaceuticals Co Ltd, a stalwart in China's pharmaceutical industry, was founded with a traditional focus but a modern vision. The company thrives on its deep expertise in developing and manufacturing traditional Chinese medicine (TCM) products, capitalizing on the rich tapestry of Eastern medicinal practices. Its extensive portfolio spans cardiovascular, cerebrovascular, and neurological disorders, areas highly pertinent to China’s aging population. By seamlessly integrating modern scientific techniques with age-old herbal wisdom, Buchang positions itself uniquely in a market that appreciates both tradition and innovation. This dual focus allows the company to tap into the growing demand for health solutions that marry efficacy with cultural familiarity. Financially, Buchang Pharmaceuticals' revenue is primarily fueled by its established healthcare products, which are marketed extensively across China’s vast healthcare network. The company shrewdly invests in building dedicated sales channels, leveraging a combination of direct engagement with healthcare professionals and strategic partnerships with medical institutions. Their emphasis on R&D ensures a steady pipeline of products, aiming to break into new therapeutic areas and expand its market presence. Buchang’s strategy to blend traditional remedies with modern delivery forms not only bolsters its domestic sales but also paves the way for potential international expansion, as global interest in holistic and alternative health solutions continues to grow. This sophisticated operational model underscores Buchang's ability to adapt and prosper amid shifting healthcare paradigms.

Intrinsic Value
17.55 CNY
Undervaluation 3%
Intrinsic Value
Price
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett